Results 91 to 100 of about 6,789 (241)
The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases [PDF]
, 2017 This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A “Guidance” document is different from a “Guideline.” Guidelines are developed by a multidisciplinary panel of experts and rate the ...
Brunt, Elizabeth M. +8 more
core +1 more source
Liver International Communications, Volume 6, Issue 4, December 2025.ABSTRACT Efficient enrolment remains a major hurdle for MASH/MASLD trials, many of which require liver fat content (LFC) ≥ 8%. We aimed to develop and validate a predictive score based on routine clinical data, optimised for patients with type 2 diabetes (T2D) to prescreen individuals likely to have elevated LFC and thereby reduce screen failures and ...
Magdalena Nowak +5 more
wiley +1 more source
Obeticholic Acid Inhibits Anxiety via Alleviating Gut Microbiota-Mediated Microglia Accumulation in the Brain of High-Fat High-Sugar Diet Mice [PDF]
, 2021 Li Wu +10 more
openalex +1 more source
MedComm, Volume 6, Issue 12, December 2025.Cancer is a complex tumor system consisting of tumor cells, immune effector cells, and all the matrix components. The intricate interactions among cells and molecular signaling pathways in this microenvironment jointly drive tumor growth, invasion, and metastasis, and significantly influence the efficacy of cancer treatment. Meanwhile, the treatment of
Ying Sun +11 more
wiley +1 more source
United European Gastroenterology Journal, Volume 13, Issue 10, Page 1955-1963, December 2025.ABSTRACT Background and Aims The European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) is a Europe‐wide network for centers of excellence in the management of rare liver diseases. We aimed to evaluate the current diagnostic and therapeutic trends of primary biliary cholangitis (PBC).
A. Gerussi +23 more
wiley +1 more source
Obeticholic Acid and Insulin Sensitivity in Overweight Patients with Prediabetes
Ожирение и метаболизмBACKGROUND. Due to its role as a risk factor for the emergence of metabolic illnesses including type 2 diabetes, cardiovascular disease, and certain cancers with pandemic evolution, obesity is a serious public health concern.
H. Amer +4 more
doaj +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: Nuclear hormone receptors
British Journal of Pharmacology, Volume 182, Issue S1, Page S242-S258, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +20 more
wiley +1 more source
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis [PDF]
, 2017 The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Abdelmalek, Manal F. +22 more
core +5 more sources
Diabetes, Obesity and Metabolism, Volume 27, Issue 12, Page 6869-6883, December 2025.Abstract Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, which include the regulation of amino acid ...
Guy W. Neff
wiley +1 more source
Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation [PDF]
, 2016 Clinicopathological concepts on acute and chronic liver disease have evolved rapidly during the last few years, with advances in general and specific treatment options and improved patient outcomes.
Alberto Quaglia +17 more
core +2 more sources